156 related articles for article (PubMed ID: 16356991)
1. Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: study conclusions do not reflect findings for celecoxib.
Feczko J
BMJ; 2005 Dec; 331(7530):1473-4. PubMed ID: 16356991
[No Abstract] [Full Text] [Related]
2. Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: what does evidence from randomised trials show about celecoxib?
Underhill JL
BMJ; 2005 Dec; 331(7530):1474-5. PubMed ID: 16356996
[No Abstract] [Full Text] [Related]
3. Celecoxib-induced upper gastrointestinal hemorrhage and ulceration.
Crawford AS; White JG
South Med J; 2002 Dec; 95(12):1444-6. PubMed ID: 12597315
[TBL] [Abstract][Full Text] [Related]
4. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
Rahme E; Bardou M; Dasgupta K; Toubouti Y; Ghosn J; Barkun AN
Rheumatology (Oxford); 2007 Feb; 46(2):265-72. PubMed ID: 16844699
[TBL] [Abstract][Full Text] [Related]
5. Celecoxib versus diclofenac and omeprazole to prevent recurrent ulcer bleeding.
Lanas A
N Engl J Med; 2003 Jun; 348(24):2464-6; author reply 2464-6. PubMed ID: 12802035
[No Abstract] [Full Text] [Related]
6. [COX-2 inhibitors--one step forward and two steps back].
Evensen S; Spigset O; Slørdal L
Tidsskr Nor Laegeforen; 2005 Apr; 125(7):875-8. PubMed ID: 15815733
[TBL] [Abstract][Full Text] [Related]
7. COX-2 inhibitors--a lesson in unexpected problems.
Drazen JM
N Engl J Med; 2005 Mar; 352(11):1131-2. PubMed ID: 15713947
[No Abstract] [Full Text] [Related]
8. [Gastrointestinal complications caused by NSAIDs. Over 60% of arthrosis patients are endangered].
MMW Fortschr Med; 2003 Mar; 145(10):60. PubMed ID: 12688036
[No Abstract] [Full Text] [Related]
9. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
Johnsen SP; Larsson H; Tarone RE; McLaughlin JK; Nørgård B; Friis S; Sørensen HT
Arch Intern Med; 2005 May; 165(9):978-84. PubMed ID: 15883235
[TBL] [Abstract][Full Text] [Related]
10. COX-2 inhibitors and Celebrex: safe or suspect?
Health News; 1999 Jun; 5(7):4. PubMed ID: 10932776
[No Abstract] [Full Text] [Related]
11. Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia.
Linder JD; Mönkemüller KE; Davis JV; Wilcox CM
South Med J; 2000 Sep; 93(9):930-2. PubMed ID: 11005360
[TBL] [Abstract][Full Text] [Related]
12. Does celecoxib use increase the risk of cardiovascular events?
Oviedo JA; Schroy PC
Gastroenterology; 2005 Oct; 129(4):1348-50. PubMed ID: 16230088
[No Abstract] [Full Text] [Related]
13. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
14. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
Moride Y; Ducruet T; Boivin JF; Moore N; Perreault S; Zhao S
Arthritis Res Ther; 2005; 7(2):R333-42. PubMed ID: 15743481
[TBL] [Abstract][Full Text] [Related]
15. Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: COX-2 inhibitors were thought of as a safe option.
Lewis MR; Kay D
BMJ; 2005 Dec; 331(7530):1474. PubMed ID: 16356997
[No Abstract] [Full Text] [Related]
16. Balancing the risks and benefits of celecoxib.
Caldwell B; Beasley R; Weatherall M; Metcalfe S
Am J Med; 2007 Jun; 120(6):e17. PubMed ID: 17524734
[No Abstract] [Full Text] [Related]
17. Benefit versus risk in the use of non-selective NSAIDs and selective COX-2 inhibitors.
Aalbers J
Cardiovasc J Afr; 2012 Jul; 23(6):356. PubMed ID: 23091830
[No Abstract] [Full Text] [Related]
18. Are rofecoxib and celecoxib safer NSAIDS?
Drug Ther Bull; 2000 Nov; 38(11):81-6. PubMed ID: 11138599
[TBL] [Abstract][Full Text] [Related]
19. Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: why were patients at major risk excluded?
Puccetti L
BMJ; 2005 Dec; 331(7530):1474. PubMed ID: 16356998
[No Abstract] [Full Text] [Related]
20. Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib?
Rahme E; Barkun AN; Toubouti Y; Scalera A; Rochon S; Lelorier J
Arthritis Rheum; 2007 Jun; 57(5):748-55. PubMed ID: 17530673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
